An excess, long-lasting increase in systemic autonomic function facilitates myocardial injury and heart failure (HF), leading to lethal cardiac outcomes. Cardiac A further large-scale investigation is needed to establish the possibility of cardiac MIBG imaging for more precisely selecting patients at increased risk or at low risk for potentially lethal arrhythmias, sudden cardiac death and/or refractory pump failure so as to optimize therapeutic interventions in patients with heart failure.
. Cardiac sympathetic innervation and function can be measured as heart-to-mediastinum ratio (HMR) of cardiac MIBG activity and washout rate of MIBG from the heart, respectively (Fig. 1a) . Recent multicenter investigations performed in North-America, Japan and Europe (9) showed that treatment with neurohormonal inhibitors significantly reduced the 5-year cardiac mortality rate from 36% to 12% in HFrEF patients in whom HMR was 1.53 or more and from 53% to 37% in HFrEF patients in whom HMR was less than 1.53. The risk reduction rate for cardiac mortality over 5 years in patients with more preserved MIBG activity, therefore, was calculated to be two-times greater than that in those with less MIBG activity: 67% versus 32%, p < 0. 05.
Thus, effects of contemporary drug treatment on cardiac mortality depend on cardiac MIBG activity, and improvement in survival rate by drug intervention may be predictable by this method.
Implantable cardioverter defibrillator and cardiac MIBG imaging
Sudden cardiac death probably due to lethal ventricular Cardiac neuroimaging with 123 I-labeled metaiodobenzylguanidine in a 73-year-old male with chronic heart failure and NYHA functional class 3 who was admitted due to progression of dyspnea. The patient had a markedly reduced late heart-to-mediastinum ratio (HMR) of MIBG activity but no accelerated washout kinetics (a). He was predicted to have an increased 5-year-mortality rate of 63% (b) and suddenly died 7.5 months later. 
Conclusions
Impairment of cardiac sympathetic innervation and function estimated by neuroimaging with MIBG can be a powerful prognostic biomarker for selecting heart failure patients at increased risk for lethal arrhythmias, sudden cardiac death and/or refractory pump failure and for predicting prognostic benefits of risk-based drug treatment, ICD and/or CRT, contributing to the optimization of a therapeutic strategy in a more cost-effective manner.
